The following trials provide information to treat various types of gastrointestinal diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse An interaction study between H 199/18 and phenytoin in healthy male and female subjects
- collapse Pharmacokinetics of H 199/18 and its main metabolites in patients with varying degrees of impaired liver function
- collapse A placebo-controlled study on the efficacy of on demand treatment with H 199/18 20 mg in maintaining control of symptoms in patients with gastroesophageal reflux disease without macroscopic esophagitis – A multicentre study
- collapse An efficacy and safety study of H 199/18 20 mg vs. omeprazole in the management of patients with gastroesophageal reflux symptoms without macroscopic esophagitis - A multicentre study
- collapse The effect of omeprazole or H 199/18 on the efficacy of clarithromycin plus amoxicillin for Helicobacter Pylori eradication and duodenal ulcer healing. A double-blind, randomised and parallel-group study.
- collapse The effect of omeprazole or H 199/18 on the efficacy of clarithromycin plus amoxicillin for the eradication of H. pylori in duodenal ulcer patients. A double blinded, randomised and parallel-group study.
- collapse A multicenter, open-label, long-term safety study of H 199/18 40 mg in subjects with healed erosive esophagitis
- collapse A multicenter, randomized, double-blind, eight week comparative efficacy and safety study of H 199/18 20 mg and omeprazole 20 mg in study subjects with erosive esophagitis
- collapse A multicenter, randomized, double-blind, eight week comparative efficacy and safety study of H 199/18 40 mg and omeprazole 20 mg in study subjects with erosive esophagitis
- collapse A multicenter, randomized, double-blind, six-month maintenance study to compare the efficacy, safety and tolerability of H 199/18 40 mg, H 199/18 20 mg, and H 199/18 10 mg with placebo in healed erosive esophagitis subjects
